search
Back to results

Phase III Study Comparing 3D Conformal Radiotherapy and Conformal Radiotherapy IMRT to Treat Endometrial Cancer (TOMOGYN)

Primary Purpose

Endometrial Cancer

Status
Terminated
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
3D conformational radiation
IMRT
Sponsored by
Centre Oscar Lambret
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Endometrial Cancer focused on measuring endometrial cancer, IMRT, age over 70

Eligibility Criteria

70 Years - undefined (Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • endometrial adenocarcinoma histologically proven
  • post op pelvic radiotherapy
  • age ≥ 70
  • performance status ≤ 2
  • MMSE ≥ 10
  • life expectancy ≥ 3 months
  • social security covered
  • signed informed consent

Exclusion Criteria:

  • type I stade IAGI and stade IAGIII without myometer infiltration, stade IIIc2 and IV adenocarcinoma
  • uterine sarcoma
  • surgery not in accordance with recommendations of Inca
  • previous uncontrolled or less than 5 years prior to diagnosis cancer
  • cons-indication for radiotherapy
  • diarrhea ≥ 3 per day
  • pelvic lymph nodes > 1cm not resected during staging
  • previous sigmoid diverticulitis, crohn disease, systemic disease, ulcerative haemorrhagic, collagenosis, infectious peritonitis
  • IMRT other than tomotherapy
  • photon energy < 10MV
  • patient under guardianship

Sites / Locations

  • Bergonie Institut
  • François Baclesse Center
  • Oscar Lambret Center
  • Centre Leon Berard
  • Institut Jean Godinot
  • René Gauducheau Center
  • Paul Strauss Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

3D conformational radiotherapy

Intensity-Modulated Radiation Therapy

Arm Description

25 * 1.8 Gy in 5 weeks (=45 Gy). 3D conformational radiation

25 * 1.8 Gy in 5 weeks (=45 Gy). IMRT

Outcomes

Primary Outcome Measures

change from baseline in acute toxicity all along the radiation
NCI CTCAE v 4.0 tox > grade 2 will be compared

Secondary Outcome Measures

geriatric intervention
number of intervention, consequences in terms of base treatment change, intervention of other specialists (except cancer)
geriatric repercussion
scales : Activities in Daily Living (ADL), Instrumental Activities in Daily Living (IADL), Mini Nutritionnal Assessment (MNA), Geriatric Depression Scale (GDS), cognitive evaluation, Cumulative Illness RAting Scale-Geriatrics (CIRS-G), sociocultural questionnaire, walking and balance
duration of the radiation
interval between first day and last day of treatment
quality of life
QLQ C30 questionnaire
late major toxicity
NCI CTCAE v 4.0
progression free survival
median time between date of inclusion and date of clinical or radialogical progression

Full Information

First Posted
July 9, 2012
Last Updated
July 19, 2017
Sponsor
Centre Oscar Lambret
Collaborators
National Cancer Institute, France
search

1. Study Identification

Unique Protocol Identification Number
NCT01641497
Brief Title
Phase III Study Comparing 3D Conformal Radiotherapy and Conformal Radiotherapy IMRT to Treat Endometrial Cancer
Acronym
TOMOGYN
Official Title
Phase III Study Comparing 3D Conformal Radiotherapy and Conformal Radiotherapy IMRT to Treat Endometrial Cancer of 70 Years Old Women : Contribution of Oncogeriatric Evaluation to the Study of Acute Toxicity
Study Type
Interventional

2. Study Status

Record Verification Date
July 2017
Overall Recruitment Status
Terminated
Why Stopped
Recruitment difficulties
Study Start Date
May 2012 (Actual)
Primary Completion Date
October 2016 (Actual)
Study Completion Date
October 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Oscar Lambret
Collaborators
National Cancer Institute, France

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Comparison of radiotherapy tolerance (two types of radiotherapy) for patients over 70 years with a endometrial cancer.
Detailed Description
Endometrial cancer is the most common form of gynecological cancer in France with 6560 new cases in 2010. Endometrial cancers occurs generally after menopause but are sometimes diagnosticated before 40 years. The 5 years Overall survival of endometrial cancer is 76% (95% for non locally advanced or non metastatic disease). Some factors are involved in disease prognostic: age, geographical origin, physical status, tumor grade, tumor histology and probably biomarkers. Some studies demonstrated that advanced age is a negative prognostic factor due to higher relapse risk and higher specific mortality. Unfortunately, Incidence of endometrial cancer will probably increase in future due to aging of the occidental population. Current treatment of endometrial cancer is based on post-operative radiation therapy: adjuvant brachytherapy or adjuvant external beam radiation therapy. However these techniques lead to serious toxicity (digestive toxicity, ileitis...) in elder patient. Consequently, pelvic radiation therapy is difficult to organize before 75 years and dangerous to perform after 80 years. However a new technique called: Intensity-modulated radiation therapy (IMRT) can make the difference. IMRT is a new high precision radiotherapy technique probably well adapted for old people, with less toxicity than current radiotherapy. Nevertheless, IMRT is not recognized as a standard radiation therapy procedure in France and Europe. Thus, goal of TOMOGYN study is to compare the tolerance of old women (at least 70 years), with endometrial cancer, treated with external beam radiation therapy or IMRT.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Endometrial Cancer
Keywords
endometrial cancer, IMRT, age over 70

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
26 (Actual)

8. Arms, Groups, and Interventions

Arm Title
3D conformational radiotherapy
Arm Type
Active Comparator
Arm Description
25 * 1.8 Gy in 5 weeks (=45 Gy). 3D conformational radiation
Arm Title
Intensity-Modulated Radiation Therapy
Arm Type
Experimental
Arm Description
25 * 1.8 Gy in 5 weeks (=45 Gy). IMRT
Intervention Type
Radiation
Intervention Name(s)
3D conformational radiation
Intervention Description
25 * 1.8 Gy in 5 weeks (=45 Gy)
Intervention Type
Radiation
Intervention Name(s)
IMRT
Intervention Description
25 * 1.8 Gy in 5 weeks (=45 Gy)
Primary Outcome Measure Information:
Title
change from baseline in acute toxicity all along the radiation
Description
NCI CTCAE v 4.0 tox > grade 2 will be compared
Time Frame
baseline, Day 5, Day 10, Day 15, Day 20, Day 25, 1 Week after end of treatment, 8 Weeks after end of treatment
Secondary Outcome Measure Information:
Title
geriatric intervention
Description
number of intervention, consequences in terms of base treatment change, intervention of other specialists (except cancer)
Time Frame
up to 6 months
Title
geriatric repercussion
Description
scales : Activities in Daily Living (ADL), Instrumental Activities in Daily Living (IADL), Mini Nutritionnal Assessment (MNA), Geriatric Depression Scale (GDS), cognitive evaluation, Cumulative Illness RAting Scale-Geriatrics (CIRS-G), sociocultural questionnaire, walking and balance
Time Frame
baseline, 6 months after end of treatment
Title
duration of the radiation
Description
interval between first day and last day of treatment
Time Frame
up to 5 weeks and a half
Title
quality of life
Description
QLQ C30 questionnaire
Time Frame
baseline, Day 5, Day 10, Day 15, Day 20, Day 25, 1 week and 8 weeks after end of treatment, 6, 12, 18 and 24 months after end of treatment
Title
late major toxicity
Description
NCI CTCAE v 4.0
Time Frame
1 week, 8 weeks, 6, 12, 18 and 24 months after the end of treatment
Title
progression free survival
Description
median time between date of inclusion and date of clinical or radialogical progression
Time Frame
an average period of 2 years

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: endometrial adenocarcinoma histologically proven post op pelvic radiotherapy age ≥ 70 performance status ≤ 2 MMSE ≥ 10 life expectancy ≥ 3 months social security covered signed informed consent Exclusion Criteria: type I stade IAGI and stade IAGIII without myometer infiltration, stade IIIc2 and IV adenocarcinoma uterine sarcoma surgery not in accordance with recommendations of Inca previous uncontrolled or less than 5 years prior to diagnosis cancer cons-indication for radiotherapy diarrhea ≥ 3 per day pelvic lymph nodes > 1cm not resected during staging previous sigmoid diverticulitis, crohn disease, systemic disease, ulcerative haemorrhagic, collagenosis, infectious peritonitis IMRT other than tomotherapy photon energy < 10MV patient under guardianship
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Le Tinier Florence, MD
Organizational Affiliation
Centre Oscar Lambret
Official's Role
Principal Investigator
Facility Information:
Facility Name
Bergonie Institut
City
Bordeaux
ZIP/Postal Code
33076
Country
France
Facility Name
François Baclesse Center
City
Caen
ZIP/Postal Code
14076
Country
France
Facility Name
Oscar Lambret Center
City
Lille
ZIP/Postal Code
59020
Country
France
Facility Name
Centre Leon Berard
City
Lyon
ZIP/Postal Code
69373
Country
France
Facility Name
Institut Jean Godinot
City
Reims
ZIP/Postal Code
51726
Country
France
Facility Name
René Gauducheau Center
City
Saint Herblain
ZIP/Postal Code
44805
Country
France
Facility Name
Paul Strauss Center
City
Strasbourg
ZIP/Postal Code
67065
Country
France

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Phase III Study Comparing 3D Conformal Radiotherapy and Conformal Radiotherapy IMRT to Treat Endometrial Cancer

We'll reach out to this number within 24 hrs